Korea/ Byoung S. Kwon, CEO - Eutilex
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The European Chamber of Commerce in Korea (ECCK) is the pre-eminent association of European companies conducting business in or related to Korea. Representing the common voice of the European business community in Korea, the ECCK aims to function as the platform for information exchange, effective communication channel to the Korean authorities and convenor of networking opportunities for European businesses. The ECCK is a non-profit and non-political organisation.
The ECCK was officially founded on 3 December 2012, upon the approval of the Ministry of Knowledge Economy (Ministry of Trade, Industry and Energy as of 2013). With its clear legal status defined under Korea’s Chamber of Commerce and Industry Act of 2008, the ECCK has focused on transparency and co-operation as its fundamental values.
The ECCK maintains its open door policy of actively listening to members’ opinions and suggestions in developing its programmes and activities. The ECCK seeks for collaboration with national chambers of commerce and European business associations to identify issues of common concern and effectively represent the interests of the European business community.
The ECCK is a strong believer in mutual prosperity. The ECCK hopes to contribute to fostering an optimal business climate for both European and local Korean companies. Moreover, as a good corporate citizen, the ECCK is determined to develop and carry out activities for the benefit of the Korean society.
The organisation is governed by the Board of Directors, entrusted with members’ mandate. The Advisory Board, comprised of national chambers and embassies, provides guidance and advice in regard to direction and activities. The Secretariat manages daily operation and activities of the Chamber.
Address
5F, Seoul Square, 416 Hangang-daero, Jung-gu,
Seoul 100-714, Korea
서울특별시중구한강대로 416 서울스퀘어 5층
(우 100-714)
Tel +82 2 6261 2700
Fax +82 2 6261 2730
E-mail ecck@ecck.eu
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based…
Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), So Ra Park MD, PhD*, comments on the regenerative medicine ecosystem in Korea, the country’s new legislative approach to the field, and…
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
See our Cookie Privacy Policy Here
